E6AP promotes prostate cancer by reducing p27 expression

about

New insights on the regulation of INK4/ARF locus expression.Proteotranscriptomic measurements of E6-Associated Protein (E6AP) targets in DU145 prostate cancer cells.

P2860

Q47141316-B26EDD83-3944-4E92-97FB-7DDD0603FCDE Q49791547-04079924-8563-4A14-A93B-C7302D993C0C

P2860

E6AP promotes prostate cancer by reducing p27 expression

Item

http://www.wikidata.org/entity/Q42335715

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

E6AP promotes prostate cancer by reducing p27 expression

@en

E6AP promotes prostate cancer by reducing p27 expression

@nl

type

Item

label

E6AP promotes prostate cancer by reducing p27 expression

@en

E6AP promotes prostate cancer by reducing p27 expression

@nl

prefLabel

E6AP promotes prostate cancer by reducing p27 expression

@en

E6AP promotes prostate cancer by reducing p27 expression

@nl

P1476

E6AP promotes prostate cancer by reducing p27 expression

@en

P2093

Andrea Russo

http://www.w3.org/2001/XMLSchema#string

Christine Khoo

http://www.w3.org/2001/XMLSchema#string

Elena Takano

http://www.w3.org/2001/XMLSchema#string

Giovanni Blandino

http://www.w3.org/2001/XMLSchema#string

Piotr Jan Paul

http://www.w3.org/2001/XMLSchema#string

Scott Williams

http://www.w3.org/2001/XMLSchema#string

Siddhartha Deb

http://www.w3.org/2001/XMLSchema#string

Sue Haupt

http://www.w3.org/2001/XMLSchema#string

Ygal Haupt

http://www.w3.org/2001/XMLSchema#string

P2860

The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily

Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland

HPV E6, E6AP and cervical cancer.

Ubiquitin and control of transcription.

E3 ubiquitin protein ligase, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth.

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.

Proteasome inhibitors in cancer therapy

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Bortezomib as a potential treatment for prostate cancer.

Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats.

P304

42939-42948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17224

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28477016

http://www.w3.org/2001/XMLSchema#string

P932

5522117

http://www.w3.org/2001/XMLSchema#string

E6AP promotes prostate cancer by reducing p27 expression

about

P2860

P2860

E6AP promotes prostate cancer by reducing p27 expression

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932